MediWound Ltd. Ordinary Shares (MDWD)
Stock · NASDAQ · Health Care
$11.87as of 10/16/2026
Price chart
Active signals
MDWD Signal Track Record
How signals performed across all stocks →What MDWD's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 49 | +1.1% | 51% | September 14, 2026 |
| Bollinger Band Breakdown | 22 | +5.8% | 82% | October 7, 2026 |
| Bollinger Band Breakout | 21 | -3.9% | 38% | June 24, 2026 |
| 200-Day Moving Average TouchActive now | 20 | -2.6% | 45% | January 28, 2026 |
| Any 20-session window (baseline) | -0.9% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MDWD
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals bu…
- Sector
- Health Care
- Industry
- Medicinal Chemicals and Botanical Products
- Employees
- 121
- Website
- www.mediwound.com/
Fundamentals
- 1-day range
- $11.87$12.22
- Market cap
- $183.44M
- P/E (trailing)
- —
- P/E (forward)
- -5.33
- EPS (trailing)
- $-1.60
- Dividend yield
- —
- Beta
- 0.01
- Avg. volume
- 84.1K
Forecasts
6 analyst ratings
MediWound Ltd. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- MDWDMediWound Ltd. Ordinary Shares$11.85▼ 2.95%Market cap $183.44MP/E —$11.9$20.03
- ACBAurora Cannabis Inc. Common Shares$3.99▼ 2.68%Market cap $184.63MP/E —$3.59$8.75
- NAGENiagen Bioscience Inc. Common Stock$2.49▼ 3.49%Market cap $240.54MP/E 12.74$2.51$7.95
- OBIOOrchestra BioMed Holdings Inc. Ordinary Shares$5.45▼ 5.05%Market cap $248.50MP/E —$3.1$6.5
- FTLFFitLife Brands Inc. Common Stock$8.39▼ 2.21%Market cap $95.88MP/E 12.92$8.5$20.15
- ISPRIspire Technology Inc. Common Stock$1.35▼ 6.25%Market cap $95.28MP/E —$1.01$3.87
- USNAUSANA Health Sciences Inc. Common Stock$15.54▲ 1.04%Market cap $274.91MP/E 32.28$12.57$23.59
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MDWD MediWound Ltd. Ordinary Shares | $183.44M | — | $11.85 | ▼ 2.95% | $11.9$20.03 |
| ACB Aurora Cannabis Inc. Common Shares | $184.63M | — | $3.99 | ▼ 2.68% | $3.59$8.75 |
| NAGE Niagen Bioscience Inc. Common Stock | $240.54M | 12.74 | $2.49 | ▼ 3.49% | $2.51$7.95 |
| OBIO Orchestra BioMed Holdings Inc. Ordinary Shares | $248.50M | — | $5.45 | ▼ 5.05% | $3.1$6.5 |
| FTLF FitLife Brands Inc. Common Stock | $95.88M | 12.92 | $8.39 | ▼ 2.21% | $8.5$20.15 |
| ISPR Ispire Technology Inc. Common Stock | $95.28M | — | $1.35 | ▼ 6.25% | $1.01$3.87 |
| USNA USANA Health Sciences Inc. Common Stock | $274.91M | 32.28 | $15.54 | ▲ 1.04% | $12.57$23.59 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Rubinstein Samuel · September 1, 2026 · Sale525 @ $12.72
- Rubinstein Samuel · September 1, 2026 · Buy525 @ $12.62
- Hess Shmuel · August 27, 2026 · Option Exercise11.0K
- Hess Shmuel · August 27, 2026 · Sale2.0K @ $12.72
- Hess Shmuel · August 26, 2026 · Option Exercise5.0K
- Hess Shmuel · August 26, 2026 · Sale1.9K @ $13
- SHAMIR NACHUM · June 3, 2026 · Buy5.8K @ $14
- SHAMIR NACHUM · June 3, 2026 · Buy175 @ $13.98
- Fox David Morton · June 1, 2026 · Buy1.8K @ $14
- Fox David Morton · June 1, 2026 · Buy10 @ $14.23
- Fox David Morton · June 1, 2026 · Buy1.7K @ $14.23
- Rubinstein Samuel · May 29, 2026 · Buy150 @ $14.33
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
MediWound Secures $3.3M U.S. Department of War Grant
MediWound has been awarded an additional $3.3 million by the U.S. Department of War. The funding is intended to advance the development of a room-temperature-stable formulation of its NexoBrid product. This grant supports the company's ongoing research efforts for its lead therapeutic asset.
MediWound Secures $3.3M U.S. Department of War Grant. MediWound has been awarded an additional $3.3 million by the U.S. Department of War. The funding is intended to advance the development of a room-temperature-stable formulation of its NexoBrid product. This grant supports the company's ongoing research efforts for its lead therapeutic asset.